Published ·
Germany's 2027 location clause: pharmaceutical warehousing must not stop at the factory gate
The 15.5% manufacturer rebate has been adopted. The location-based exemption remains open and should recognise GDP warehouses, cold chains and resilient CEE distribution as essential supply infrastructure.
What has been adopted – and what has not
From 1 January 2027, certain patent-protected medicines will generally be subject to a total manufacturer rebate of 15.5%. This was adopted on 10 July 2026. An automatic lower rate for companies manufacturing in Germany has not been adopted. A joint BMG/BMWE expert panel is due to submit a legally compliant location-clause proposal by 30 September 2026.
Why production alone does not create supply security
A medicine becomes available only when release, packaging, serialisation, storage status, temperature, inventory, picking and transport are controlled. Manufacturing capacity without qualified warehousing and distribution cannot prevent shortages. GDP warehousing is critical infrastructure between factory and patient.
Which logistics investments should count
Qualifying investment should create measurable additional supply capacity: new 15–25 °C or 2–8 °C space, redundant sites, committed safety stock, backup power, qualified monitoring, recall readiness and alternative transport lanes. Long-term commitment, GDP quality, named products and auditable indicators matter more than warehouse ownership.
Cheb as an operational bridge to Germany and CEE
Cheb sits directly at the German border and combines short transit times into Germany with access to Czechia, Poland, Austria and other CEE markets. A qualified GDP site can hold buffer stock, support launches, provide backup capacity and organise cross-border distribution. For German supply, proximity and response time may matter more than a formal German address.
A German bonus or a European resilience incentive?
A Germany-only preference may conflict with EU internal-market and state-aid rules. A more robust approach would assess response time, redundancy, qualified capacity, alternative routes and proven ability to supply German and European patients.
Funding, evidence and clawback
Health insurers demand full funding of exemptions, while companies need predictable criteria. A workable model requires minimum investment, multi-year commitments, product-linked evidence, caps and clawback rules. Relief should follow available capacity, not intent alone.
Inter-Pharma: demonstrating operational supply impact
Inter-Pharma translates investment plans into controlled operations: capacity, temperature profile, batches, FEFO, safety stock, SLA, contingency operation, partner qualification and European lanes are designed together. Explore GDP pharmaceutical warehousing in Cheb or discuss a warehousing and distribution project.
Frequently asked questions
Do companies manufacturing in Germany automatically receive a lower rebate?
No. The general 15.5% rate has been adopted; the detailed location clause has not.
Could GDP warehousing qualify as investment?
This remains open. There is a strong supply-security case for measurable, long-term warehousing and distribution capacity.
Why is Cheb relevant to Germany?
Cheb is directly on the German border and enables short routes plus redundant supply to Germany and CEE.
What should evidence include?
Investment value, capacity, temperature profile, products, duration, service levels, KPIs and clawback rules.